In Alzheimer’s disease (AD), the development of disease-modifying therapies targeting MAPT (microtubule-associated protein tau) is supported by the strong correlation between tau deposition and the onset and progression of cognitive decline (1–5). This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.